Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue

TAKATO UENO1, TAKUJI TORIMURA2, TORU NAKAMURA2, RAMADOSS SIVAKUMAR1, HITOMI NAKAYAMA3, SYUICHI OTABE3, XIAOHONG YUAN3, KENTARO YAMADA3, OSAMU HASHIMOTO2, KINYA INOUE2, HIRONORI KOGA2 and MICHIO SATA2

1Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan; Divisions of 2Gastroenterology; 3Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, Japan

Received February 5, 2009; Accepted April 2, 2009

DOI: 10.3892/ijmm_00000200

Abstract. We examined whether or not epigallocatechin-3-gallate (EGCG) improves liver injury of nonalcoholic steatohepatitis (NASH) model mice expressing nuclear sterol regulatory element-binding protein 1c (nSREBP-1c) in adipose tissue. nSREBP-1c transgenic C57BL6 mice aged 30 weeks were divided into group 1 (no treatment), group 2 (ascorbic acid alone), group 3 (ascorbic acid and 0.05% EGCG), and group 4 (ascorbic acid and 0.1% EGCG). At 42 weeks, we performed measurement of liver weight to body weight, biochemical assays, morphometry of liver specimens, immunohistochemistry for 8-hydro-2'-deoxyguanosine (8-OhdG), and Western blotting for insulin and TNF-α signalings. Ratio of liver weight to body weight in the high dose EGCG-treated group (group 4) was significantly lower than those of groups 1 and 2 (p<0.05 and <0.01, respectively). Blood ALT, glucose, total cholesterol, and triglyceride levels of group 4 were significantly low compared with those of the EGCG-non-treated group (groups 1 and 2) (p<0.05, respectively). The degrees of steatosis, inflammation, ballooning hepatocytes and Mallory-Denk bodies in group 4 significantly improved compared with those in other groups (p<0.05, respectively). The 8-OhdG immunolocalization in liver tissues of the group 4 obviously decreased compared with those of groups 2 and 3. For Western blotting, the expressions of insulin receptor substrate-1 (IRS-1) and phosphorylated IRS-1 (pIRS-1) in liver tissues of group 4 increased compared with those of groups 2 and 3. On the other hand, the expressions of pAkt, pIKKβ and pNF-κB decreased compared with those of groups 2 and 3. From these results, EGCG reduces inflammation, insulin resistance and oxidative stress, and suppresses liver injury in nSREBP-1c transgenic mice.

Introduction

Although the obesity epidemic is a worldwide phenomenon, the severity of the epidemic differs greatly from region to region. The prevalence of obesity among Japanese adults is 3.4% in males and 3.8% in females, and is around one tenth of that in the USA (1). In addition, currently in Japan almost 30% of adult males and females over 50 years old are obese. This rising incidence of obesity parallels the dramatic increase in fatty liver in these age groups. Based on annual health checks, the prevalence of fatty liver diagnosed by ultrasonography increased from 10% in 1980 to 20-40% in 2000 among adults. Thus, nonalcoholic fatty liver disease (NAFLD) is now emerging as the most common liver disease in Japan (2,3). The recent worldwide rise in the number of patients with nonalcoholic steatohepatitis (NASH) tends to parallel the increase in metabolic syndrome, which includes obesity, type 2 diabetes and hyperlipidemia (4).

NAFLD mainly comprises of simple steatosis that is considered benign, however some patients have nonalcoholic steatohepatitis (NASH), which is a clinicopathological entity characterized by the development of hepatic histological changes resembling those induced by excessive alcohol intake that occur in the absence of alcohol abuse (5). Some patients with NASH progress to end-stage liver disease, as cirrhosis and hepatocellular carcinoma in as little as a decade, and treatment of NASH is therefore very important. However, no single agent improves the histological end points and long-term outcomes (6-8).
Lipodystrophic mice expressing nuclear sterol regulatory element-binding protein 1c (nSREBP-1c) in the adipose tissues show severe insulin resistance, and develop NASH. These animals have marked fatty liver accompanied by hyperlipidemia, hyperleptinemia, and hyperadiponectinemia (9). Immunoreactive 8-hydroxy-2'-deoxyguanosine was observed in the livers of these model mice, suggesting that in addition to insulin resistance, oxidative stress is involved in the development of the NASH-like lesions.

On the other hand, epigallocatechin-3-gallate (EGCG), a type of green tea polyphenol, is a major component of green tea extract, and has the effects of body-fat reduction (10) and antihyperlipidemia (11,12). Therefore, EGCG is useful for NASH patients with obesity and/or hyperlipidemia, but there are no reports indicating that EGCG shows improvement of NASH. In the present study, we examined whether or not catechins improve liver injury of NASH model mice expressing nSREBP-1c in adipose tissue.

Materials and methods

Animals and treatment. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Kurume University School of Medicine. Transgenic C57BL6 mice (Jackson Lab, ME) expressing nSREBP-1c in adipose tissue were purchased from The Jackson Laboratory (Bar Harbor, ME) (13). We identified nSREBP-1c transgenic mice by amplifying genomic DNA isolated from tails by polymerase chain reaction using a forward primer 5'-CTACATTTGCTTTCTGCAAC-3', and used heterozygous transgenic mice in the following studies. They were bred in our laboratory, mating with wild-type C57BL6 mice, and then bred in the animal facility, mating with wild-type C57BL6 mice. All the animals were used in this study. The animals were divided into four groups [group 1, mice given distilled water alone (n=6); group 2, mice given distilled water containing 0.005% ascorbic acid alone (n=6); group 3, mice given distilled water containing 0.005% ascorbic acid and low dose EGCG (0.05%) (n=6); group 4, mice given distilled water containing 0.005% ascorbic acid and high dose EGCG (0.1%) (n=6). EGCG, epigallocatechin-3-gallate; *p<0.05, **p<0.01 compared with group 4.]

Table 1. Ratio of liver weight to body weight and blood biochemical assay.

<table>
<thead>
<tr>
<th>Group</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver weight/ body weight x100 (%)</td>
<td>12.8±2*</td>
<td>15.2±1.8*</td>
<td>12.4±5.6</td>
<td>7.2±4.8</td>
</tr>
<tr>
<td>AST</td>
<td>200±132</td>
<td>183±8</td>
<td>248±153</td>
<td>187±57</td>
</tr>
<tr>
<td>ALT</td>
<td>321±260*</td>
<td>309±47*</td>
<td>286±257</td>
<td>151±67</td>
</tr>
<tr>
<td>Glucose</td>
<td>230±35</td>
<td>274±23</td>
<td>272±45</td>
<td>315±54</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>50±23</td>
<td>56±19*</td>
<td>35±25</td>
<td>30±7</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>156±26</td>
<td>176±17*</td>
<td>132±54</td>
<td>107±42</td>
</tr>
<tr>
<td>Free fatty acid</td>
<td>508±171</td>
<td>498±68</td>
<td>466±116</td>
<td>496±126</td>
</tr>
<tr>
<td>Phospholipid</td>
<td>288±47*</td>
<td>309±41*</td>
<td>240±101</td>
<td>199±57</td>
</tr>
</tbody>
</table>

Histological diagnosis and morphometry of liver specimens. Paraffin-embedded sections of the liver were stained with either hematoxylin-eosin for standard microscopy and Azan-Mallory stain to observe the localization of extracellular matrix. The specimens were reviewed by two independent pathologists. Each specimen was assigned to one of the following histological subgroups for the purpose of comparative analysis, type 1, simple steatosis affecting >33% of the lobules; type 2, steatosis and lobular inflammation; type 3, steatosis and ballooning; type 4, steatosis, ballooning hepatocytes and Mallory-Denk bodies or fibrosis. We dealt with types 3 and 4 as NASH, as described previously (14). In addition, we performed morphometry of liver specimens using the histological scoring system of Kleiner et al (15).
Immunohistochemistry. Immunoreactive products of 8-hydroxy-2'-deoxyguanosine (8-OhdG), a marker of oxidative DNA damage, in the liver were examined. Paraffin sections were incubated overnight with mouse monoclonal anti-8-OhdG antibody (Japan Institute for the Control of Aging, Fukuroi, Japan), followed by incubation with alkaline phosphatase-labeled horse antimouse IgG (Vector, Burlingame, CA) and visualization by diaminobenzidine. The degree of 8-OhdG immunolocalization in the liver tissues was categorized as 0, 1, 2 or 3. That is, 0, none in liver tissue; 1, <1/3 in the intrahepatic lobules; 2, 1/3-2/3 in the intrahepatic lobules; and 3, >2/3 in the intrahepatic lobules.

Western blotting. Western blotting was performed using anti-insulin receptor (IR), anti-insulin receptor substrate (IRS)-1 and anti-phosphorylated IRS-1 (pIRS-1), anti-pGSK3α/β antibodies for insulin signaling, and using anti-Akt, -pAkt, -IκBα, -pIκBα, -NF-κB and -pNF-κB antibodies for TNF-α signaling in liver tissues. Whole extracts were prepared from liver tissues using Triton lysis buffer-containing protease and phosphatase inhibitors. Protein concentration of the extracts was determined, and 40 μg of protein was electrophorased on 10% SDS-polyacrylamide gels. The gels were then blotted onto the nitrocellulose membrane.

Statistical analysis. Numerical data were expressed as means ±SD. Student's t test was performed to assess statistical significance among each group. P-values <0.05 were considered significant.

Results

Changes of body weight of mice in the four groups. Body weight of mice in the four groups gradually increased throughout the course of the experiment period as shown in Fig. 1, but there was no significant difference among each group.
Ratio of liver weight to body weight at week 43. Ratio (percentage of expression) of liver weight to body weight in the high dose EGCG-treated group (group 4) was lowest compared with that of other groups (group 1, 12.8±2; group 2, 15.2±1.8; group 3, 12.4±5.6; and group 4, 7.2±4.8), and the difference between group 4 and groups 1 and 2 was significant (p<0.05 and <0.01, respectively) (Table I).

Biochemical assays containing serum biological markers. Blood ALT, total cholesterol, triglyceride and phospholipid levels of group 4 were significantly low compared with those of groups 1 and 2 (p<0.05, respectively) (Table I). The elevation of serum ALT, AST levels by EGCG treatment was not recognized. In addition, there were no significant differences between AST, free fatty acid, and glucose levels between any of the groups.

Morphometry of liver specimens. The degrees of steatosis, intralobular fibrosis, ballooning hepatocyte appearance and Mallory-Denk body appearance in group 4 significantly decreased compared with those in other groups (p<0.05) (Table II, Fig. 2).

Immunohistochemistry. Immunoreactive products for anti-8-OhdG antibody localized in the cytoplasm of hepatocytes, especially deformed hepatocytes with fat droplets (Fig. 3). The 8-OhdG immunolocalization in liver tissues of group 4 showed an obvious decrease compared with those of other groups, and the difference between the degree of 8-OhdG immunolocalization in group 4 and that of groups 2 and 3 was significant (p<0.05) (Table II, Fig. 3).

Western blotting. In Western blotting, the expressions of IR and pIRS-1 in liver tissues of group 4 increased compared with those of other groups. On the other hand, the expressions of pAkt, pIKKβ and pNF-κB in liver tissues of group 4 decreased compared with those of other groups (Fig. 4).

Discussion
Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome. The metabolic syndrome is characterized by insulin resistance, which is produced by a complex interaction between genetic factors, macronutrient intake and lifestyle that alters the cytokine profile, cell biology and biochemical milieu of the liver, adipose tissue and striated muscle. The resultant disequilibrium in lipid homeostasis causes triglycerides to accumulate in the liver (16). An increase in oxidative stress, due to the generation of reactive oxygen species as a result of mitochondrial abnormalities and induction of the cytochrome P-450 system is one mechanism by which the nonalcoholic fatty liver develops into NASH (4). The pathogenesis of cytologic ballooning and Mallory-Denk body formation and their role in NAFLD remain to be defined. In addition, inflammation and fibrosis are likely to be secondary to cirrhosis, hepatocellular carcinoma and death (2,3,17).
EGCG is an antioxidant and chemopreventive polyphenol that is found in green tea. It blocks activation of Ap-1 or NF-κB (18). EGCG has shown the inhibition of activation of IKKß, phosphorylation and subsequent degradation of IκB (18). In addition, EGCG suppresses the proliferation of hepatic stellate cells and production of extracellular matrix in the hepatic fibrosis (19-21). Yumei et al reported that EGCG induced the de novo synthesis of glutathione and antifibrogenic effects in passaged rat hepatic stellate cells (22,23).

In the present study, green tea polyphenols containing EGCG showed effects of reducing inflammation, insulin resistance and oxidative stress (24-26), and improved the liver injury of transgenic mice expressing nSREBP-1c in the adipose tissue. EGCG inhibits nSREBP-1c expression in adipose tissues and Akt, IκBα and NF-κB expressions of liver tissues, and improves the insulin resistance of the liver tissues by promoting the functional recovery of the insulin receptor, insulin receptor substrate-1 (IRS-1) and glycogen synthase kinase (GSK) in the nSREBP-1c transgenic NASH model mice. The direct effect of EGCG to this model mouse is unclear. Its mechanism is likely due to the antioxidant and chemoprevention effects of EGCG (18).

Ingestion of tea rich catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men (27). In obese individuals, body fat mainly accumulates in submucosal and visceral adipose tissue. Obesity alters both the cellular composition and function of adipose tissue. Adipose tissue of obese individuals contains an increased number of macrophages. Macrophages, adipocytes, and other cellular components of adipose tissue produce numerous circulating inflammatory markers including pro- and anti-inflammatory factors, chemokines, growth factors, and proteases that include a systemic inflammatory state and insulin resistance seen in individuals with increased body mass index (28). In this study, there is no significant difference among the four groups for body weight. Probably, the visceral adipose tissue of nSREBP-1c transgenic mice is less than that of wild type C57BL6 mice, and the significant difference is not recognized among each group.

The liver component of this metabolic disorder is NAFLD, which includes a spectrum of liver pathology ranging from steatosis to cirrhosis. Steatosis is often seen in obese individuals, and both presence and severity of steatosis correlate positively with adiposity. Increased hepatic free fatty acid oxidation that occurs in steatotic livers increases the generation of reactive oxygen species. Increased hepatocyte exposure to reactive oxygen species generates a state of oxidant stress and mitochondrial dysfunction, including hepatocellular injury and activation of hepatic stellate cells (HSC). In NAFLD, intestine-originated endotoxin accumulates the substance in the liver rather than to escape from liver. Increased levels of glucose and insulin up-regulate the synthesis of transforming growth factor-ß, angiotensin II, leptin, adiponectin and so on by HSC (29-31), and develop to the hepatic fibrosis.

In this study, there was no evidence of side effects by EGCG treatment. It will be important to clearly determine whether EGCG or green tea consumption can be used as a tool to prevent the development of NASH.

Acknowledgements

This research was supported by a Grant-in-Aid from the University and Society Collaboration and from COE Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References


